Physician profile
John Quigley
NPI 1912010323
$131,792.69
in general payments reported to CMS, 2019-2025
28 companies · $27K in 2025
The $27K reported for 2025 was more than what 88% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $14K · 2021: $16K · 2022: $19K · 2023: $14K · 2024: $1,767 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Consulting Fee: $15K · Travel and Lodging: $3,681 · Food and Beverage: $1,602 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,020 · Education: $19.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,250.00 |
| Consulting Fee | $15,138.50 |
| Travel and Lodging | $3,680.52 |
| Food and Beverage | $1,601.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,020.00 |
| Education | $19.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $45,208.61 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $34,055.12 | 2019-2024 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $13,528.21 | 2019-2023 | Oxlumo |
| Jazz Pharmaceuticals INC. | $7,440.77 | 2025 | |
| Amgen INC. | $5,105.83 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $4,607.60 | 2019-2021 | |
| Genzyme Corporation | $4,428.82 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $4,000.00 | 2022 | |
| Tanabe Pharma America, INC. | $3,075.00 | 2022 | |
| Celgene Corporation | $2,821.44 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $1,743.33 | 2021-2022 | |
| Cti Biopharma Corp. | $1,725.00 | 2022 | |
| Janssen Biotech, INC. | $1,482.57 | 2019 | |
| Dova Pharmaceuticals | $1,451.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $591.33 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $175.89 | 2025 | Brukinsa, Tevimbra |
| Mitsubishi Tanabe Pharma Development America, INC. | $115.26 | 2020 | |
| Merck Sharp & Dohme LLC | $61.67 | 2022-2023 | Keytruda, Lynparza |
| Pfizer INC. | $60.02 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $50.00 | 2019 | |
| Genentech USA, INC. | $25.55 | 2024 | Perjeta, Kadcyla, Phesgo |
| Seagen INC. | $21.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2023 | Ninlaro |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Quigley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.